These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 25072955)

  • 1. Another option for menopausal vasomotor symptoms without negative impact on weight and sexual function.
    Bachmann G
    Menopause; 2014 Oct; 21(10):1036-7. PubMed ID: 25072955
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety of low-dose paroxetine.
    Pines A
    Climacteric; 2014 Jun; 17(3):313-4. PubMed ID: 24945035
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of low-dose paroxetine 7.5 mg on weight and sexual function during treatment of vasomotor symptoms associated with menopause.
    Portman DJ; Kaunitz AM; Kazempour K; Mekonnen H; Bhaskar S; Lippman J
    Menopause; 2014 Oct; 21(10):1082-90. PubMed ID: 24552977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials.
    Simon JA; Portman DJ; Kaunitz AM; Mekonnen H; Kazempour K; Bhaskar S; Lippman J
    Menopause; 2013 Oct; 20(10):1027-35. PubMed ID: 24045678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial.
    Stearns V; Beebe KL; Iyengar M; Dube E
    JAMA; 2003 Jun; 289(21):2827-34. PubMed ID: 12783913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paroxetine (Brisdelle) for hot flashes.
    Med Lett Drugs Ther; 2013 Oct; 55(1428):85-6. PubMed ID: 24165707
    [No Abstract]   [Full Text] [Related]  

  • 7. Do SSRIs and SNRIs reduce the frequency and/or severity of hot flashes in menopausal women.
    Stubbs C; Mattingly L; Crawford SA; Wickersham EA; Brockhaus JL; McCarthy LH
    J Okla State Med Assoc; 2017 May; 110(5):272-274. PubMed ID: 28649145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing vasomotor symptoms in women after cancer.
    Pinkerton JV; Santen RJ
    Climacteric; 2019 Dec; 22(6):544-552. PubMed ID: 31081391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose paroxetine (7.5 mg) improves sleep in women with vasomotor symptoms associated with menopause.
    Pinkerton JV; Joffe H; Kazempour K; Mekonnen H; Bhaskar S; Lippman J
    Menopause; 2015 Jan; 22(1):50-8. PubMed ID: 25137243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Low-Dose Paroxetine for the Treatment of Hot Flushes in Surgical and Physiological Postmenopausal Women: Systematic Review and Meta-Analysis of Randomized Trials.
    Riemma G; Schiattarella A; La Verde M; Zarobbi G; Garzon S; Cucinella G; Calagna G; Labriola D; De Franciscis P
    Medicina (Kaunas); 2019 Aug; 55(9):. PubMed ID: 31480427
    [No Abstract]   [Full Text] [Related]  

  • 11. Paroxetine: a first for selective serotonin reuptake inhibitors - a new use: approved for vasomotor symptoms in postmenopausal women.
    Weber L; Thacker HL
    Womens Health (Lond); 2014 Mar; 10(2):147-54. PubMed ID: 24601805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and tolerability of SSRI/SNRIs in the treatment of vasomotor symptoms in menopausal women: a systematic review.
    Handley AP; Williams M
    J Am Assoc Nurse Pract; 2015 Jan; 27(1):54-61. PubMed ID: 24944075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective serotonin reuptake inhibitors fluvoxamine and paroxetine restore forced exercise-induced temperature dysregulation in ovariectomized mice.
    Ikeda M; Egawa T; Yamauchi A; Sohda Y; Koga A; Tominaga K; Shuto H; Kataoka Y
    Eur J Pharmacol; 2008 Jan; 579(1-3):439-44. PubMed ID: 18155696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diary of hot flashes reported upon occurrence: results of a randomized double-blind study of raloxifene, placebo, and paroxetine.
    Simon JA; Chandler J; Gottesdiener K; Lazarus N; He W; Rosenberg E; Wagner JA; Denker AE
    Menopause; 2014 Sep; 21(9):938-44. PubMed ID: 24569618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SSRIs for menopausal hot flashes: a promise yet to be delivered.
    Thurston RC
    Menopause; 2007; 14(5):820-2. PubMed ID: 17667151
    [No Abstract]   [Full Text] [Related]  

  • 16. Serotonergic agents as an alternative to hormonal therapy for the treatment of menopausal vasomotor symptoms.
    Stearns V
    Treat Endocrinol; 2006; 5(2):83-7. PubMed ID: 16542048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Noradrenergic and serotonergic modulation to treat vasomotor symptoms.
    Albertazzi P
    J Br Menopause Soc; 2006 Mar; 12(1):7-11. PubMed ID: 16513016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extinguishing hot flash therapy.
    Loprinzi C; Bostwick JM
    Menopause; 2013 Mar; 20(3):248-9. PubMed ID: 23422868
    [No Abstract]   [Full Text] [Related]  

  • 19. A review of paroxetine for the treatment of vasomotor symptoms.
    Slaton RM; Champion MN; Palmore KB
    J Pharm Pract; 2015 Jun; 28(3):266-74. PubMed ID: 25107421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of paroxetine in the management of hot flashes in gynecological cancer survivors: Results of the first randomized single-center controlled trial.
    Capriglione S; Plotti F; Montera R; Luvero D; Lopez S; Scaletta G; Aloisi A; Serra GB; Angioli R
    Gynecol Oncol; 2016 Dec; 143(3):584-588. PubMed ID: 27751589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.